

Press Release

Astellas Announces Personnel Changes and Organizational Changes

Tokyo, February 8, 2017 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the personnel changes and organizational changes as below.

1. Appointments of Senior Corporate Executive effective on April 1, 2017

Name	New Title	Current Title
Yasumasa Masuda	CEO's Office	CFO
Kenji Yasukawa	CSTO & CCO	CSTO
Mitsunori Matsuda	President, Pharmaceutical Technology	President, Technology

CEO: Chief Executive Officer

CFO: Chief Financial Officer

CSTO: Chief Strategy Officer

CCO: Chief Commercial Officer

2. Appointments of Corporate Executive effective on April 1, 2017

Name	New Title	Current Title
Kiyotaka Hayashi	CEO's Office	Divisional Senior Vice President, Sales Operation, Japan Sales & Marketing
Chikashi Takeda	CFO	Corporate Vice President, Corporate Finance & Control
Fumiaki Sakurai	CAO & CECO	Corporate Vice President, Human Resources
Akihiko Iwai	Divisional Senior Vice President, Candidate Discovery Science Labs., DDR	Divisional Senior Vice President, Research Portfolio & Science, DDR
Toru Yoshimitsu	Corporate Vice President, Corporate Finance & Control	Corporate Vice President, Product & Portfolio Strategy
Taiji Sawamoto	Vice President, Research Program Management, DDR	Vice President, Clinical Pharmacology, Development

CAO: Chief Administrative Officer

CECO: Chief Ethics & Compliance Officer

DDR: Drug Discovery Research

3. Resignation of Senior Corporate Executive effective on June 19, 2017

Name	Title (effective on April 1, 2017)
Yasumasa Masuda	CEO's Office

4. Resignation of Corporate Executive effective on June 19, 2017

Name	Title (effective on April 1, 2017)
Kiyotaka Hayashi	CEO's Office

5. Appointment of Senior Corporate Executive effective on June 19th, 2017

Name	Title (effective on April 1, 2017)
Masatoshi Kuroda	President, Asia & Oceania Business

6. New Corporate Executives effective on June 19, 2017

Name	Title (effective on April 1, 2017)
Tadashi Hara	Divisional Senior Vice President, Strategic Business Management, Japan Sales & Marketing
Hideki Shima	Divisional Senior Vice President, Technology Planning & Administration, Pharmaceutical Technology
Shigeki Tanaka	Vice President, Japan-Asia Clinical Development 1, Development

7. Personnel Changes effective on April 1, 2017

Name	New Title	Current Title
Linda Friedman	General Counsel	Senior Vice President, General Counsel, Astellas US LLC
Koichiro Morihira	Head of Intellectual Property	Vice President, Intellectual Property
Naoki Sogo	Corporate Vice President, Product & Portfolio Strategy	Executive Director, Product & Portfolio Strategy
Akira Kamimura	Vice President, Accounting & Tax	Executive Director, Corporate Finance & Control
Yasuhiro Tsutsui	Vice President, Executive Office	Executive Director, Strategic Business Management, Japan Sales & Marketing

Ryusuke Nakajima	Corporate Vice President, Human Resources	Executive Director, Human Resources
Noriyuki Masuda	Vice President, Research Planning & Administration, DDR	Divisional Senior Vice President, Research Administration, DDR
Rika Hirota	Vice President, Research Regulatory Management, DDR	Vice President, Bioscience Research Labs., DDR
Yuichi Tomura	Vice President, Research Portfolio Planning, DDR	Executive Director, Innovation & Research Portfolio Planning, DDR
Shunichiro Matsumoto	Divisional Senior Vice President, Innovation & Incubation Research Labs., DDR	Vice President, Innovation Management
Shigeki Kawabata	Vice President, Evolving Medical Solutions, DDR	Vice President, Evolving Medical Solutions
Masaaki Hirano	Divisional Senior Vice President, Modality Research Labs., DDR	Vice President, Medicinal Chemistry Research Labs., DDR
Manabu Murakami	Vice President, Clinical Pharmacology, Development	Executive Director, Astellas Institute for Regenerative Medicine
Yuzuru Komano	Vice President, Japan-Asia Clinical Development 2, Development	Senior Director, Japan-Asia Clinical Development 2, Development
Manabu Beppu	Vice President, Japan-Asia Data Science, Development	Vice President, Japan-Asia Clinical Development Administration, Development
Yasushi Ikeda	Vice President, Medical Science Liaison, Medical Affairs Japan	Vice President, Medical Research, Medical Affairs Japan
Katsutoshi Nakamura	Vice President, Project & Product Management, Pharmaceutical Technology	Vice President, Technology Product Management, Technology
Nobuyuki Tanaka	Vice President, Supply Chain Management, Pharmaceutical Technology	President, Astellas US Technologies, Inc.

Kazuhiko Hayashida	Divisional Senior Vice President, Sales Operation, Japan Sales & Marketing	General Manager, Chugoku Branch, Japan Sales & Marketing
Masao Toda	General Manager, Saitama Branch, Japan Sales & Marketing	Executive Director, Tokyo Branch, Japan Sales & Marketing
Yoshiyuki Naoi	General Manager, Chugoku Branch, Japan Sales & Marketing	General Manager, Shikoku Branch, Japan Sales & Marketing
Yuusuke Kumagai	General Manager, Shikoku Branch, Japan Sales & Marketing	Executive Director, Human Resources Development, Japan Sales & Marketing
Katsushi Takenaka	General Manager, Kyushu Branch, Japan Sales & Marketing	General Manager, Saitama Branch, Japan Sales & Marketing
Hiroshi Hamaguchi	Vice President, Business Planning, Asia & Oceania Business	Head of South East & South Asia
Keita Masujima	Vice President, Marketing, Asia & Oceania Business	Vice President, Business Planning, Asia & Oceania Business

8. Organizational Changes effective on April 1, 2017

Executive Office

Executive Office will expand its roles and responsibilities to support a globalized Astellas' Top Management structure in an effective way and to better respond to a shift to stricter corporate governance in Japan.

Drug Discovery Research

To precisely and rapidly respond to changes in the healthcare environment and continuously create innovation on the forefront of such changes, Drug Discovery Research will be reorganized as the Attachment 1.

Japan-Asia Clinical Development Administration

To strengthen global alignment and increase business efficiency, Japan-Asia Clinical Development Administration will be dissolved. The medical writing function and the clinical development administration function will be incorporated into Japan-Asia Data Science and Japan-Asia Planning & Administration respectively.

Medical Affairs

From the perspective of responding to inquiries from healthcare professionals related to scientific information in an appropriate and timely manner and ensuring the medical science liaison activities with consistently high quality and compliance in Japan, the medical science liaison functions existed under Medical Science will be consolidated and expanded. Medical Science Liaison will be newly established. Medical Research will be dissolved and its functions will be transferred to Medical Science.

Technology

In order to strengthen its global operations and contract manufacturing organization management, and to enhance administrative structure, Technology will be restructured into new function structure. Technology Planning & Administration and Technology Product Management will be restructured to Technology Planning & Administration, Project & Product Management and Supply Chain Management. Technology will be named as “Pharmaceutical Technology” to accurately emphasize its function in the manufacture of pharmaceutical products.

Asia & Oceania Business

Business Planning will be reorganized and consist of the strategic planning function which will develop and promote affiliates’ strategy, and the license & budget control function. Marketing & Business Management will be reorganized to Marketing consisting of the product management function and the talent & product planning function.

###

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

Attachment 1

